Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel in Participants With Moderate-to-Severe Acne: The Patient Journey
In two phase 3 clinical trials, fixed-dose, triple-combination CAB demonstrated good efficacy/safety. All 6 CAB-treated cases achieved substantial (>70%) lesion reductions, with 5/6 achieving treatment success or 2-grade reduction in severity by week 12. Transient cutaneous safety/tolerability severity increases generally resolved to baseline values by week 12. These clinical study cases reinforce the importance of patient education regarding adherence, expectations, and AEs. J Drugs Dermatol. 2024;23(11):1017-1024. doi:10.36849/JDD.8639.
Authors
- Zoé Kececioglu Draelos (ORCID: https://orcid.org/0000-0001-9803-7415)
- Linda Stein Gold (ORCID: https://orcid.org/0000-0002-2758-1605)
- Julie Harper (ORCID: https://orcid.org/0000-0001-7181-8721)
- Leon Kircik (ORCID: https://orcid.org/0000-0002-0831-2151)
- Lawrence F. Eichenfield (ORCID: https://orcid.org/0000-0002-2760-0474)
- Joshua Zeichner (ORCID: https://orcid.org/0000-0003-2154-988X)
- Hilary E. Baldwin (ORCID: https://orcid.org/0009-0002-3540-3670)
- M. Gold (ORCID: https://orcid.org/0009-0004-3743-693X)
Publication Details
- Journal
- Journal of Drugs in Dermatology
- Published
- 2024-10-01
- DOI
- https://doi.org/10.36849/jdd.8639
- Primary Topic
- Acne and Rosacea Treatments and Effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00